塞来昔布预防乳腺癌患者紫杉类药物相关的急性疼痛综合征的临床研究

Clinical Study of Celecoxib in Preventing Taxane-Associated Acute Pain Syndrome in Patients with Breast Cancer

摘要: 目的：分析塞来昔布在预防乳腺癌患者紫杉类药物相关急性疼痛综合征(T-APS)的效果。方法：抽取2024年1月~2025年4月期间在我院接受化疗治疗(均使用含多西他塞化的化疗药物)的早期乳腺癌患者100例，以随机信封法分组，在化疗治疗期间未进行其他干预的50例患者为对照组，在化疗治疗期间使用塞米昔布干预的50例患者为塞来昔布组，对比两组患者紫杉类药物相关急性疼痛综合征总发生率、严重紫杉类药物相关急性疼痛综合征发生率、不同时间节点(化疗后7 d、14 d、21 d)疼痛严重程度[简单疼痛量表(BPI)]、生活质量[癌症治疗–乳房功能评估(FACT-B)]。结果：(1) 塞来昔布组患者紫杉类药物相关急性疼痛综合征总发生率及严重紫杉类药物相关急性疼痛综合征发生率均低于对照组(P < 0.05)；(2) 化疗后各个时间节点，塞来昔布组患者BPI评分均明显低于对照组(P < 0.05)；(3) 化疗后各个时间节点，塞来昔布组患者FACT-B评分均明显高于对照组(P < 0.05)。结论：乳腺癌患者使用紫杉类药物化疗期间，使用塞来昔布可显著降低患者并发紫杉类药物相关急性疼痛综合征的发生风险，有助于改善患者生活质量。

Abstract: Objective: To analyze the effect of celecoxib in preventing taxane-associated acute pain syndrome (T-APS) in patients with breast cancer. Methods: A total of 100 patients with early-stage breast cancer who received chemotherapy (all involving docetaxel-based regimens) at our hospital from January 2024 to April 2025 were selected. The patients were divided into two groups using the random envelope method. The control group consisted of 50 patients who did not receive any additional interventions during chemotherapy, while the celecoxib group included 50 patients who received celecoxib intervention during chemotherapy. The following outcomes were compared between the two groups: the overall incidence rate of taxane-associated acute pain syndrome (T-APS), the incidence rate of severe T-APS, pain severity at different time points (7 days, 14 days, and 21 days after chemotherapy) using the Brief Pain Inventory (BPI), and quality of life using the Functional Assessment of Cancer Therapy-Breast (FACT-B). Result: (1) The total incidence of taxane-associated acute pain syndrome and the incidence of severe taxane-associated acute pain syndrome in the celecoxib group were lower than those in the control group (P < 0.05); (2) At various time points after chemotherapy, the BPI scores of patients in the celecoxib group were significantly lower than those in the control group (P < 0.05); (3) At various time points after chemotherapy, the FACT-B scores of patients in the celecoxib group were significantly higher than those in the control group (P < 0.05). Conclusion: During chemotherapy with taxane, celecoxib can significantly reduce the risk of patients with breast cancer complicated with taxane-associated acute pain syndrome, and help improve the quality of life of patients.